Newsgroup: it.economia.borsa
Titolo: CELL T (domani riammessa!)

eheh meno male cosi sbologno quelle che avevo a 0.064 prese sett scorsa 2 
ore prima della "FOLLE" sospensione !! domani ci sara un comunicato della 
societa' mahh :o( 

 ha scritto nel messaggio 
news:qxFml.35093$8Z.1...@tornado.fastwebnet.it...


 MA ANCHE A milano??
si attende comunicato pensavo di trovarlo gia' stamane ma nada bhaaaa

 ha scritto nel 

tič
SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq 
and MTA: CTIC) announced today that, following the issuance of a press 
release in Italy in response to information requested by the Italian 
securities regulatory authority, CONSOB, regarding CTI's business operations 
and financial condition, which was also furnished on a Form 8-K in the U.S. 
on February 17, 2009, the Borsa Italiana has confirmed that it will 
re-initiate trading in CTI's shares effective with the open of trading in 
Italy on February 18, 2009. Based on the foregoing and CTI's communications 
with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in 
the Company's shares prior to the open of the regular trading session on 
NASDAQ on February 18, 2009. 

 ha scritto nel 

di oggi, però mi pare sempre la stessa solfa
SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq 
and MTA: CTIC) announced today that updated safety and efficacy data from 
the phase III trial of pixantrone provides further support for a robust 
clinical benefit for pixantrone when used as single agent therapy in the 
treatment of multiple relapsed aggressive non-Hodgkin's lymphoma (NHL). On 
an intent-to-treat analysis, pixantrone recipients who achieved a complete 
remission did so during the first 2 cycles of therapy, compared to 4 cycles 
among standard chemotherapy recipients, (1.9 months vs. 3.6 months, 
pixantrone vs. standard chemotherapy). The duration of response in the 
patients was similar in the 37% of pixantrone patients who had either a 
partial or complete response compared to the 14% of comparator patients with 
a major response. However, the overall progression free survival (PFS) was 
significantly longer in the pixantrone arm (4.7 months vs. 2.6 months, 
hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy). 
Thirty-two percent (32%) of pixantrone patients received all 6 cycles of 
therapy, with 84% receiving 5 of 6 cycles of treatment. Pixantrone 
recipients had a low incidence of severe neutropenia complicated by either 
fever or documented infections, or severe vomiting or diarrhea. Pixantrone 
patients also experienced a low incidence of hair loss, a very common side 
effect of other drugs in this class. Overall, the incidence of serious 
adverse events was similar between pixantrone and the control arm. The 
pixantrone patients had a higher incidence of leucopenia and neutropenia and 
numerically more severe cardiac events (4 vs 2) than in the control arm. 
Disease progression reported as an adverse event was less frequent in the 
pixantrone than in the control arm (1.5% vs. 13.4%).
"We were impressed to see that 84% of patients received at least 5 cycles of 
pixantrone therapy with a median total dose of 1,475 mg, despite having had 
significant prior therapy with doxorubicin, an agent in a similar class with 
cumulative cardiotoxicity," noted Jack Singer, M.D., Chief Medical Officer 
at CTI. "The rapid time-to-response data coupled with the relatively low 
incidence of traditional anthracycline toxicities and a safety profile that 
compares favorably to standard chemotherapy, positions pixantrone to live up 
to the promise of providing patients with relapsed aggressive NHL a 
meaningful clinical benefit."
CTI announced in November 2008 that it had achieved the primary efficacy 
endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). 
Patients randomized to treatment with pixantrone achieved a high rate of 
confirmed and unconfirmed complete remissions compared to patients treated 
with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 
4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in 
the standard chemotherapy arm achieved a confirmed complete remission 
compared to 8/70 (11%) of pixantrone recipients.
CTI expects to begin submission of a rolling New Drug Application (NDA) and 
request priority review for pixantrone to treat relapsed aggressive non- 
Hodgkin's lymphoma ( NHL) in the first quarter of 2009. If granted priority 
review a decision on the NDA could occur before the end of 2009.
The study received Special Protocol Assessment approval from the U.S. Food 
and Drug Administration (FDA) in 2004, and pixantrone has received fast 
track designation for this indication.